Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: France,Spain,Israel,Lithuania,Germany,Poland,United Kingdom,Belgium,Italy,Hungary
nct
Update Il y a 5 ans
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer (NSCLC).
Country
Australia
,
Austria
,
Belgium
,
Canada
,
China
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Israel
,
Italy
,
Latvia
,
Lithuania
,
Netherlands
,
New Zealand
,
Philippines
,
Poland
,
Portugal
,
Russian Federation
,
Singapore
,
South Africa
,
Spain
,
Switzerland
,
Taiwan, Province of China
,
Thailand
,
Turkey
,
Ukraine
,
United Kingdom
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants
This 2 arm study will evaluate the efficacy and safety of oseltamivir in the seasonal prophylaxis of influenza in immunocompromised participants (as represented by transplant recipients). Transplant recipients enrolled when influenza is circulating in the community will be randomized to receive oseltamivir syrup or capsules 30 milligrams (mg) to 75 mg daily (depending on body weight) or placebo for 12 weeks. Influenza symptoms and safety data will be recorded throughout the study.
Country
Belgium
,
Canada
,
Czech Republic
,
Estonia
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Lithuania
,
Poland
,
Spain
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Patients will be randomised to receive either placebo or the study drug for a period of 30 weeks, in addition to their standard Parkinsonian medications. During the first 8 weeks, the patient's levodopa doses may be adjusted if necessary by the investigator. For the remainder of the 22 weeks, all medications should be kept stable. Patients will be required to attend the clinic twice during the screening period and then a further 8 times during the treatment period. They will be required to complete home diaries where they will record their motor function. In addition, their doctor will assess their Parkinson's disease during the clinic visits. There will also be blood draws for safety and pharmacokinetic and pharmacogenomics evaluation. Following the treatment and assessment period, they will return to the clinic one month later for follow up.
Country
Austria
,
Belgium
,
Czech Republic
,
Estonia
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Lithuania
,
Poland
,
Portugal
,
Serbia
,
South Africa
,
Spain
,
Sweden
,
United Kingdom
,
organs
None
Specialty
None
Closed trial
More information
1